Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinńr
Tiermedizin
  WELCOME  
vetcontact
Vetrinńr
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinńr
Tiermedizin
  CONTACTS  
vetcontact
Vetrinńr
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinńr
Tiermedizin
  PROFESSION  
vetcontact
Vetrinńr
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinńr
Tiermedizin
  INSIGHT  
vetcontact
Vetrinńr
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinńr
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinńr
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english espa˝ol polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
0.2% brimonidine tartrate in the glaucomatous Beagle
Glaucoma is a common problem in dogs, showing also marked breed predilections. In this study, the effect of 0.2% brimonidine tartrate applicated one to three times daily was evaluated. It is effective, but side effects must be considered and therefore it should be combined with other drugs.

The objective of this study was to evaluate the changes in intraocular pressure (IOP) in glaucomatous dogs after instillations of 0.2% brimonidine once, twice and three times daily in single day studies, and after twice and three times daily for 4 days in multiple dose studies.

We studied eight Beagles with inherited primary open angle glaucoma.

Applanation tonometry (IOP), pupil size (PS) and heart rate (HR) measurements were obtained at 8 am, 10 am, 1 pm, 3 pm and 5 pm. T

he studies were divided into: eight glaucoma dogs and five of the eight dogs that demonstrated greater response to 0.2% brimonidine.

Single-dose drug studies are divided into placebo (0.5% methylcellulose), 0.2% brimonidine administered once daily (8 am); twice daily (8 am and noon); and three times daily (8 am, noon and 5 pm).

The 5-day multiple-dose studies included: day 1, no drug; and 4 days, 0.2% brimonidine instillations either twice daily (8 am and 2 pm) or three times daily (8 am, 2 pm and 9 pm). Statistical comparisons between drug groups included control (nondrug) and treated (placebo/0.2% brimonidine) eyes for both single- and multiple-dose studies.

The mean ┬▒ SEM diurnal decrease in IOP in the eight glaucomatous Beagles for the control and placebo eyes were 3.4 ┬▒ 4.7 and 5.4 ┬▒ 2.8 mmHg, respectively.

The mean ┬▒ SEM diurnal decrease in IOP after 0.2% brimonidine once, twice and three times daily was 6.4 ┬▒ 3.5, 8.0 ┬▒ 6.1 and 9.8 ┬▒ 8.1 mmHg, respectively; this trend was not significant statistically.

Significant miosis occurred starting 2 h postinstillations, and the resultant mean ┬▒ SD pupil size was 2.7 ┬▒ 0.3 mm.

A significant decrease in heart rate also occurred (12%).

In the five most responsive dogs the changes in PS and HR during these studies were similar to the larger group, but significant decreases in IOP occurred at most measurement times. I

n the multiple-dose study with 0.2% brimonidine twice daily the mean ┬▒ SEM decrease in IOP for day 1 to day 4 was 5.0 ┬▒ 1.3, 5.7 ┬▒ 1.3, 1.4 ┬▒ 3.3 and 4.9 ┬▒ 1.3 mmHg, respectively.
When 0.2% brimonidine was instilled three times daily the mean ┬▒ SEM diurnal IOP decrease was from day 1 to day 4 and was 0.75 ┬▒ 1.3, 2.4 ┬▒ 1.5, 1.2 ┬▒ 2.7 and 1.4 ┬▒ 1.8 mmHg, respectively.

The mean change in pupil diameter was 1.3 ┬▒ 0.5 mm. Decrease in HR averaged 22%. In the same single-dose studies with the five most responsive dogs, PS and HR were similar, but the decreases in IOP were significant at more measurement intervals.

We conclude that 0.2% brimonidine produces a decrease in IOP in dogs, a statistically significant miosis, and a reduced heart rate (1222%).

However, because of the limited drug-induced ocular hypotension, brimonidine should be combined with other drugs when used for the glaucomas in the dog.


Source: Gelatt, Kirk N. & MacKay, Edward O. (2002): Effect of single and multiple doses of 0.2% brimonidine tartrate in the glaucomatous Beagle. In: Veterinary Ophthalmology 5 (4), 253-262.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Toceranib phosphate (Palladia®) in canine gastrointestinal stromal tumorsmembers
Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. HighÔÇÉrisk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting. This recently online published study reviews cases of toceranib phosphate use in dogs with GISTs and provides initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value.

  • Radioactive iodine uptake in hyperthyroid cats after rh-TSHmembers
  • Punica granatum associated with hepatotoxicosis in cattle
  • Hypoechoic tissue changes in dogs with malignant prostatic lymphomamembers
  • Emphysematous gastritis in dogs and catsmembers
  • Primary pulmonary histiocytic sarcoma in dogsmembers
  • Determining prognosis in canine sepsis members
  • Correlation of plasma and tear glucose, creatinine and urea nitrogen in catsmembers
  • Perineal hernias in dogs - always a bilateral problem?members
  • Pharmacokinetic of gabapentin in catsmembers
  • Follicular development of canine ovaries stimulated by eCG plus hCGmembers
  • Gastrointestinal effects following acupuncture in healthy dogsmembers
  • Bilateral repair of apparently unilateral perineal hernias in dogsmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved